Pharmacological targets of drugs employed in chronic venous and lymphatic insufficiency

International Angiology

Volumn 21, Issue 2 SUPPL. 1, 2002, Pages 33-39

  Boisseau, M R ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Anoxia; Venous insufficiency, diagnosis; Venous insufficiency, drug therapy; Venous insufficiency, prevention and control

Indexed keywords

ASCORBIC ACID; DIOSMIN; FABROVEN; FLAVONOID; HESPERIDIN; MELILOTUS EXTRACT; NORADRENALIN; NUCLEOSIDE; PHLEBODRIL; PYCNOGENOL; RUSCUS ACULEATUS EXTRACT; RUTOSIDE DERIVATIVE; SAPONIN DERIVATIVE;

BLOOD RHEOLOGY; CHRONIC VEIN INSUFFICIENCY; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; DYSTROPHY; HUMAN; LEG EDEMA; LEG PAIN; LEG VEIN; LYMPHATIC SYSTEM DISEASE; MICROCIRCULATION; REVIEW; SYMPTOM; VEIN COMPLIANCE; VEIN DILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; VENOUS CIRCULATION;

EID: 0036625649     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Auteri A, Blardi P, Frigerio C, de Lillo L, di Perri T. Pharmacodynamics of troxerutine in patients with chronic venous insufficiency: correlations with plasma drug levels. Int J Clin Pharmacol Res 1990; 10:235-41.
2. Nicolaides AN. Investigation of chronic venous insufficiency. A consensus statement. Circulation 2000; 102:E126-63.
3. Preziosi P, Galan P, Aissa M, Hercberg S, Boccalon H , Prevalence of venous insufficiency in French adults of the SUVIMAX cohort. Supplementation en vitamines et mineraux antioxydants. Int Angiol 1999; 18: 171-5.
4. Jantet G. RELIEF Study: first consolidated European data. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology 2000; 51: 31-7.
5. Widmer L, Biland L, Barras JP. Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int Angiol 1990; 9:105-10.
6. Prerovsky I, Roztocil K, Hlavova A, Koleilat Z, Razgova L, Oliva I. The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double-blind study. Angiologica 1972; 9:408-14.
7. Cloarec M, Clement R, Griton P. A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology 1996; 11:76-82.
8. Unkauf M, Rehn D, Klinger J, de la Motte S, Grossmann K. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung 1996; 46:478-82.
9. Vin F, Chabanel A, Taccoen A, Ducros J, Gruffaz J, Hutinel B et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology 1994; 9:71-6.
10. Bergqvist D, Hallböök T, Lindblad B, Lindhagen A. A double-blind trial of O-(β-hydroxylethyl)-rutoside in patients with chronic venous insufficiency. Vasa 1981; 10:253-60.
11. Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C et al. Efficacy of Daflon 500 mg in venous leg ulcer healing. A double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997; 48:77-85.
12. Filis KA, Georgopoulos SE, Papas SC, Votteas V, Bastounis EA. Therapeutic efficacy of flavonoids in oedema following reperfusion on acutely ischaemic legs. Int Angiol 1999; 18:327-30.
13. Parrado F, Buzzi A. A study of the efficacy and tolerability of a preparation containing ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clin Drug Invest 1999; 18:255-61.
14. Kranendonk SE, Koster AM. A double-blind clinical trial of the efficacy and tolerability of O-(β-hydroxyehyl)-rutosides and compression stockings in the treatment of leg oedema and symptoms following surgery for varicose veins. Phlebology 1993; 8:77-81.
15. Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside and Daflon. Angiology 2000; 51:197-205.
16. Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology 2000; 51:535-44.
17. Rehn D, Golden G, Nocker W, Diebschlag W, Lehmacher W. Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency. Arzneimittelforschung 1993; 43:1060-3.
18. Boccalon H, Causse C, Yubero L. Comparative efficacy of a single daily dose of two capsules Cyclo 3 Fort in the morning versus a repeated dose of one capsule morning and noon. A one-month study. Int Angiol 1998; 17:155-60.
19. Boada J, Nazco J. Clinical effectiveness of venotonic drugs: a meta-analysis. Methods Find Exp Clin Pharmacol 1996; 18(Suppl B):15-8.
20. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994; 23:244-50.
21. Chauveau M. Drug treatments of chronic venous insufficiency: pharmacoclinical evaluation. Presse Méd 1994; 23:243-9.
22. Cesarone MR, Belcaro G, Nicolaides AN. Visualisation des vasa vasorum par Doppler puissance dans les veines normales et variqueuses. Angiologie 1998; 50: 49-55.
23. Taccoen A, Lebard C, Borie H, Poullain JC, Zuccarelli F, Gerentes I et al. Measurement of oxygen tension in normal and varicose veins walls. J Mal Vasc 1996; 21(Suppl C):259-65.
24. Taccoen A, Lebard C, Zuccarelli F. Laser Doppler flux in normal and varicose long saphenous vein wall. Phlebology 1996; 11:146-9.
25. Jäger K, Eichlisberger R, Jeanneret C, Lobs KH. Pharmacodynamic effects of ruscus extract (Cyclo 3 Fort®) on superficial and deep veins in patients with primary varicose veins. Assessment by duplex sonography. Clin Drug Invest 1999; 17:265-73.
26. Jimenez Cossio JA, Magallon Ortin PJ, Capilla Montes MT, Coya Vina J. Therapeutic effect of ruscus extract in lymphoedemas of the extremities. In: Vanhoutte PM, editor. Return circulation and norepinephrine: an update. Paris-London: John Libbey Eurotext, 1991: 111-9.
27. Marcelon G, Pouget G, Tisné-Versailles J. Effects of ruscus on the adrenoceptors of the canine lymphatic thoracic drugs. Phlebology 1988; 3(Suppl 1):109-12.
28. McHale NG. Mechanism of noradrenaline action in lymphatic vessels. In: Vanhoutte PM, editor. Return circulation and norepinephrine: an update. Paris-London: John Libbey Eurotext, 1991:73-88.
29. Cluzan RV, Alliot F, Ghabboun S, Pascot M. Treatment of secondary lymphedema of the upper limb with Cyclo 3 Fort. Lymphology 1996; 29:29-35.
30. Bouskela E, Cyrino FZGA. Possible mechanisms for the effects of ruscus extract on microvascular permeability and diameter. Clin Hemorheol 1994; 14(Suppl): S23-36.
31. Bouskela E, Cyrino FZ, Bougaret S. Effects of Cyclo 3 Fort on microvascular reactivity and the venoarteriolar reflex in diabetic hamsters. Clin Hemorheol Microcirc 1997; 17:351-6.
32. Boisseau MR, Freyburger G, Busquet M, Roudaut MF. Hemorheological disturbances in venous insufficiency after induced stasis. Clin Hemorheol 1989; 9:161-3.
33. Le Devehat C, Boisseau M, Vimeux M, Bondoux G, Bertrand A. Hemorheological factors in the pathophysiology of venous disease. Clin Hemorheol 1989; 9: 861-70.
34. Le Devehat C, Khodabandehlou T, Vimeux M, Dougny M. The effects of Cyclo 3 Fort treatment on hemorheological disturbances during a provoked venous stasis in patients with chronic venous insufficiency. Clin Hemorheol 1994; 14(Suppl):S53-63.
35. Le Devehat C, Khodabandehlou T, Vimeux M, Bondoux G. Hemorheological concepts in venous insufficiency and implications for treatment with ruscus extract. In: Vanhoutte PM, editor. Return circulation and norepinephrine: an update. Paris-London: John Libbey Eurotext 1991:225-36.
36. Boisseu MR, Taccoen A, Garreau C, Vergnes C, Roudaut MF, Garreau-Gomez B. Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J Cardiovasc Surg 1995; 36:369-74.
37. Zuccarelli A, Taccoen A, Razavian M, Chabanel A. Increasing erythrocyte aggregability with the progressive grades of chronic venous insufficiency: importance and mechanisms. J Cardiovasc Surg 1995; 36: 387-91.
38. Azaceta G, Romero S, Moreno JA, Vaquerizo A, Olave T, Lorente C et al. Hemorheological profile in chronic venous insufficiency after surgery. Haemostasis 1999; 29:219-24.
39. Baurain R, Dom G, Trouet A. Protecting effect of Cyclo 3 Fort and its constituents for human endothelial cells under hypoxia. Clin Hemorheol 1994; 14(Suppl 1): S15-21.
40. Bouaziz N, Michiels C, Janssens D, Berna N, Eliaers F, Panconi E et al. Effect of ruscus extract and hesperidin methylchalcone on hypoxia-induced activation of endothelial cells. Int Angiol 1999; 18:306-12.
41. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. Angiology 2000; 51: 19-23.
42. Domange JR, Bougaret S, Yubero L. Pharmacological studies of Cyclo 3 Fort and its constituents (ruscus extract, hesperidin methyl chalcone, ascorbic acid). An up to date review. Chn Hemorheol 1994;14(Suppl 1):S7-13.
43. Browse NL, Burnand KG. The cause of venous ulceration. Lancet 1982;ii:243-5.
44. Gajraj H, Browse NL. Fibrinolytic activity and calf pump failure. Br J Surg 1991;78:1009-12.
45. Haas S, Lill G, Stiller A, Geissdorfer K, Blumel G. Influence of ruscus extract and methylhesperidine chalcone on the fibrinolytic activity of the vein wall. In: Vanhoutte PM, editor. Return circulation and norepinephrine: an update. Paris-London: John Libbey Eurotext, 1991:157-62.
46. Coleridge Smith PD. The microcirculation in venous hypertension. Vasc Med 1997;2:203-13.
47. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J 1988;296:1693-5.
48. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge Smith PD. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 1997;26:265-73.
49. Peschen M, Lahaye T, Hennig B, Weyl A, Simon JC, Vanscheidt W. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. Acta Derm Venereol 1999;79;27-32.
50. Hahn TL, Whitfield R, Salter J, Granger DR, Unthank JL, Lalka SG, Evaluation of the role of intracellular adhesion molecule 1 in a rodent model of chronic venous hypertension. J Surg Res 2000;88:150-4.
51. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous diseases. Eur J Vasc Endovasc Surg 1998;15:342-9.
52. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000;31:456-61.
53. Bosanquet N. Costs of venous ulcers: from maintenance therapy to investment programmes. Phlebology 1992;7(Suppl 1):S44-6.